Indication

Second-Line Treatment

1 clinical trial

1 product

Clinical trial

A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients With Preserved Liver Function

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Product